Autosomal Recessive Spinocerebellar Ataxia 10 (SCAR10)

Autosomal recessive spinocerebellar ataxia 10 (SCAR10) is a rare, inherited brain disorder that mainly affects the cerebellum—the part that coordinates balance, speech, and eye movements. It is caused by harmful changes (variants) in the ANO10 (TMEM16K) gene. Symptoms often begin in the teens to early adulthood and include unsteady gait, clumsy hands, slurred speech (dysarthria), abnormal eye movements (nystagmus), and gradual cerebellar shrinkage on MRI. Some people develop increased reflexes, mild thinking changes, or seizures. Progression is usually slow over years. SCAR10 follows an autosomal-recessive pattern, so a person must inherit two non-working copies of ANO10. There is currently no approved disease-modifying drug; care focuses on rehabilitation, safety, and treating symptoms. NCBI+2rarediseases.info.nih.gov+2

ANO10 encodes anoctamin-10, a protein in cell membranes and the endoplasmic reticulum that helps move chloride ions and scramble phospholipids (lipids in cell membranes). Loss of ANO10 function appears to disturb membrane homeostasis and calcium-signaling in cerebellar neurons (especially Purkinje cells), gradually impairing coordination. This biological “mis-wiring” explains why balance, speech, eye control, and fine hand skills are most affected in SCAR10. Understanding this target helps researchers explore therapies that stabilize neuronal signaling or protect cerebellar cells. SpringerLink+1

Autosomal recessive spinocerebellar ataxia 10 is a rare brain disorder that slowly damages the cerebellum, the part of the brain that controls balance, speech, and smooth movement. “Autosomal recessive” means a child must inherit one faulty copy of the same gene from each parent to get the disease. SCAR10 is caused by harmful changes (variants) in a gene called ANO10 (also known as TMEM16K). Most people develop symptoms in the late teenage years or in young adulthood, and the problems get worse slowly over time. Typical signs are unsteady walking, clumsy hand movements, slurred speech, abnormal eye movements (like nystagmus or “shaking” eyes), and sometimes brisk reflexes or mild stiffness. Brain scans usually show shrinkage (atrophy) of the cerebellum. In some people, tests show low levels of coenzyme Q10 in muscle, and a few may improve with coenzyme Q10 supplements. SpringerLink+4NCBI+4rarediseases.info.nih.gov+4

---

Other names

• SCAR10 (Spinocerebellar ataxia, autosomal recessive 10)

• ANO10-related spinocerebellar ataxia

• Autosomal recessive cerebellar ataxia type 10

• ARCA3 (a label used by some labs for ANO10-related ataxia) jewishgenetics.org+1

---

Types

There is no official set of “subtypes,” but experts often describe clinical patterns that help counseling and care:

1. Classic, late-onset cerebellar form. Onset in the 2nd–4th decade with imbalance, limb clumsiness, slurred speech, nystagmus, and slowly progressive cerebellar atrophy on MRI. PMC+1

2. Cerebellar-plus form. The same cerebellar signs plus one or more of: brisk reflexes or mild pyramidal signs, peripheral neuropathy, or cognitive decline. EMG may show lower motor neuron involvement in some patients. rarediseases.info.nih.gov+1

3. Early-adult vs. later-adult onset. Age at first symptoms varies; later onset often progresses more slowly. PMC

4. CoQ10-deficiency–associated form. A subset shows low muscle CoQ10 and can be considered for supplementation. NCBI+1

---

Causes

In genetics, “cause” refers to disease mechanisms and the factors that lead to damage. For SCAR10, all root causes trace back to pathogenic variants in ANO10. The items below explain mechanisms, contributors, and risk conditions that flow from that genetic cause.

1. Pathogenic ANO10 variants (primary cause). Disease starts when both ANO10 copies have harmful changes (homozygous or compound heterozygous). thejcn.com

2. Loss of phospholipid “scramblase” activity. ANO10 helps move lipids across membranes; loss upsets membrane lipid balance and harms cerebellar cells. SpringerLink

3. Abnormal endoplasmic reticulum (ER) membrane handling. Faulty lipid distribution in the ER stresses neurons and Purkinje cells. SpringerLink

4. Defects in endosomal transport. Trafficking problems disturb neuronal health and signaling. SpringerLink

5. Cerebellar Purkinje cell dysfunction. These cells are key for coordination; their injury leads to ataxia. (Inferred from ANO10-linked cerebellar atrophy patterns.) PMC

6. Impaired calcium-activated membrane processes. Anoctamins are calcium-responsive proteins; disruption may alter neuronal responses. SpringerLink

7. Secondary coenzyme Q10 deficiency in muscle. Some patients show low CoQ10, suggesting mitochondrial stress in tissues. SpringerLink

8. Gene dosage from consanguinity. Parents who are related can both carry the same rare variant, increasing risk for an affected child. (General recessive genetics principle; SCAR10 reported in such contexts.) BioMed Central

9. Founder variants in some populations. Certain communities may share specific ANO10 changes due to ancestry. (Described in case series expanding ANO10 alleles.) PMC+1

10. Axonal neuropathy mechanisms. When peripheral nerves are affected, walking control worsens. rarediseases.info.nih.gov

11. Oculomotor circuit involvement. Damage to cerebellar/brainstem circuits causes nystagmus and saccade problems. rarediseases.info.nih.gov

12. Pyramidal tract involvement. Brisk reflexes or mild spasticity can reflect corticospinal tract impact. rarediseases.info.nih.gov

13. Cognitive network involvement. Some patients have progressive cognitive decline, pointing to broader network effects. rarediseases.info.nih.gov

14. Mitochondrial stress from membrane imbalance. Lipid dysregulation can disturb energy production pathways. (Mechanistic inference supported by ANO10 biology and CoQ10 data.) SpringerLink+1

15. Oxidative stress. Low CoQ10 reduces antioxidant capacity in muscle and possibly neurons. SpringerLink

16. Calcium signaling imbalance. Anoctamin family proteins interact with calcium; disruption can alter neuronal firing stability. SpringerLink

17. Synaptic and cerebellar circuit maladaptation. Long-term network changes follow cell-level injury, worsening coordination. PMC

18. Age-related neuronal vulnerability. Adult-onset reflects when damaged pathways reach a failure point. PMC

19. Gene–environment neutrality (no known triggers). Unlike toxic ataxias, no specific toxins are proven to “cause” SCAR10; the driver is the gene defect itself. Authoritative overviews stress the genetic basis. NCBI

20. Misdiagnosis delays (indirect driver of progression). Late recognition delays supportive care; recognition improves management even if it does not change genetics. (Observed across ARCA literature.) PMC

---

Symptoms

1. Unsteady walking (gait ataxia). People sway, stagger, or widen their stance to avoid falling. rarediseases.info.nih.gov

2. Clumsy hand and arm moves (limb ataxia). Fine tasks like buttons, keys, or handwriting become hard. NCBI

3. Slurred or slow speech (dysarthria). Words sound blurred because mouth and tongue control is poor. NCBI

4. Shaking eye movements (nystagmus). Eyes move back and forth; vision may blur. rarediseases.info.nih.gov

5. Overshooting eye jumps (hypermetric saccades). Eyes “jump past” the target, then correct. rarediseases.info.nih.gov

6. Brisk reflexes. Knee or ankle jerks are more active than normal. rarediseases.info.nih.gov

7. Mild stiffness or pyramidal signs. Tone can feel increased; leg movement may feel tight. rarediseases.info.nih.gov

8. Tremor or shaky movements. The hands can shake during action because the cerebellum is not smoothing movement. (Cerebellar sign described across ARCA/SCAR10 spectrum.) PMC

9. Poor balance when standing still. Standing with feet together can be hard; people may sway. (Typical cerebellar feature.) PMC

10. Numbness or tingling from nerve involvement. Some people have peripheral neuropathy that worsens balance. rarediseases.info.nih.gov

11. Lower motor neuron signs on EMG. Muscles may show changes that fit nerve or motor unit stress. rarediseases.info.nih.gov

12. Cognitive changes. Some develop mild thinking or memory problems over time. rarediseases.info.nih.gov

13. Swallowing trouble (dysphagia). Speech and throat control may make swallowing slower. (Cerebellar-related bulbar issues are reported in ataxias.) PMC

14. Fatigue. Extra effort to keep balance and coordinate movement makes people tired. (Common in progressive ataxias.) PMC

15. Slow, steady progression. Symptoms usually worsen over years, not weeks or months. PMC

---

Diagnostic tests

A) Physical exam (bedside)

1. Full neurological exam. A doctor checks eye movements, speech, hand-nose testing, heel-to-shin, rapid alternating movements, reflexes, strength, sensation, and gait. The pattern of cerebellar signs plus brisk reflexes can point to SCAR10. rarediseases.info.nih.gov

2. Gait assessment. Walking heel-to-toe, turning, and tandem gait show instability typical of cerebellar disease. PMC

3. Oculomotor exam. The clinician looks for nystagmus and overshooting saccades, which are common in SCAR10. rarediseases.info.nih.gov

4. Speech evaluation. Dysarthria (slurred speech) supports a cerebellar disorder. NCBI

5. Reflex and pyramidal signs check. Increased deep tendon reflexes or mild spastic signs suggest cerebellar-plus involvement. rarediseases.info.nih.gov

B) Manual bedside coordination tests

6. Finger-to-nose and finger-to-finger. Shows limb ataxia and dysmetria (overshoot). PMC

7. Heel-to-shin. Checks leg coordination; wobble or drift suggests cerebellar disease. PMC

8. Rapid alternating movements (diadochokinesia). Slowness or irregular rhythm fits cerebellar dysfunction. PMC

9. Romberg and stance tests. Sway with feet together helps document balance problems; in pure cerebellar ataxia people often sway even with eyes open. PMC

10. Tandem gait and pull-test. Heel-to-toe walking and brief backward pull test gauge postural control and fall risk. PMC

C) Lab and pathological studies

11. Targeted or exome-based genetic testing. Confirms pathogenic variants in ANO10 and proves the diagnosis. Testing can be single-gene, panel, or exome/genome depending on local practice. thejcn.com+2Myriad Genetics+2

12. Coenzyme Q10 level (muscle; sometimes plasma). Some patients show low CoQ10, which may guide treatment trials. SpringerLink

13. Muscle biopsy (select cases). When done for CoQ10 measurement or if diagnosis is unclear, muscle can show low CoQ10; otherwise biopsy is not always needed once genetics are positive. SpringerLink

14. Rule-out labs for other ataxias. Vitamin E, thyroid tests, B12, copper/ceruloplasmin, and metabolic screens help exclude treatable mimics before or alongside genetic confirmation. (Standard ARCA work-ups described in reviews.) BioMed Central

15. Family (carrier) testing and counseling. Once an ANO10 variant is found, parents and adult relatives can consider carrier testing for planning. Myriad Genetics

D) Electrodiagnostic tests

16. Nerve conduction studies (NCS). May show axonal neuropathy in those with nerve involvement, explaining numbness or imbalance. rarediseases.info.nih.gov

17. Electromyography (EMG). Can reveal lower motor neuron involvement in some cases; helps explain weakness or cramps. rarediseases.info.nih.gov

18. Evoked potentials (as needed). Visual or somatosensory tests can map pathway delays when symptoms suggest broader involvement; mainly supportive. (General ARCA practice.) PMC

E) Imaging tests

19. Brain MRI. The key imaging test; usually shows cerebellar atrophy that supports a cerebellar degenerative process. NCBI+1

20. Spinal MRI (select cases). Considered if symptoms or exam suggest spinal cord involvement or other causes; helps rule out mimics, though SCAR10 mainly affects the cerebellum. (ARCA diagnostic frameworks.) BioMed Central

Non-Pharmacological Treatments (therapies & other supports)

1) Coordinative physiotherapy (balance + gait training)
A structured program that blends coordination drills (e.g., tandem steps, obstacle walking), balance challenges, gait practice, and functional tasks can reduce ataxia severity and improve walking confidence. Multi-component physiotherapy shows meaningful drops in SARA scores (a standard ataxia scale) and lowers fall risk when done consistently. Programs typically start 2–3 sessions/week with daily home practice. Consistency beats intensity; even mild daily work helps the cerebellum “re-learn” patterns. A physical therapist individualizes difficulty to keep you safe while still challenging balance. Purpose: maintain mobility, reduce falls, keep independence. Mechanism: repetitive, task-specific practice strengthens remaining cerebellar circuits and compensatory sensory strategies (vision, proprioception), improving motor learning. Frontiers+1

2) Vestibular rehabilitation
When dizziness, visual blurring with head turns, or imbalance is present, a therapist can prescribe gaze-stabilization drills (e.g., VOR x1, VOR x2), habituation, and balance retraining. In degenerative cerebellar disease, vestibular therapy improves balance confidence, sensory integration, and fall risk—benefits seen even when tests show cerebellar impairment. Sessions typically occur weekly for 4–8 weeks with daily home work. Purpose: reduce dizziness/instability, sharpen gaze during movement, improve safety. Mechanism: adaptation (brain recalibrates eye–head reflexes), substitution (using vision/somatosensation), and habituation (desensitization to motion). PMC+1

3) Intensive coordination blocks (“boot camps”)
Short blocks (2–3 weeks) of daily, high-repetition coordination training (e.g., treadmill with harness, over-ground practice, task-oriented circuits) can produce short-term gains in walking speed and stability that are maintained with home programs. Purpose: accelerate progress and break plateaus. Mechanism: massed practice enhances motor learning and plasticity in residual cerebellar pathways. BMJ Open

4) Speech therapy for dysarthria
A speech-language pathologist (SLP) trains clearer articulation, breath support, pacing, and prosody using structured protocols. Programs improved speech intelligibility and quality of life in SCA cohorts when delivered continuously. Home metronome pacing and loudness drills help day-to-day communication. Purpose: improve clarity and reduce communication fatigue. Mechanism: repetitive motor speech practice strengthens compensatory muscle patterns and timing control. PMC+1

5) Swallowing therapy
SLPs assess risk of choking/aspiration and teach safe-swallow strategies: posture changes (chin-tuck), diet texture modifications, effortful swallow, and timing/sequence cues. Early referral prevents weight loss, dehydration, and pneumonia. Purpose: safer eating/drinking and adequate nutrition. Mechanism: targeted exercise and compensations improve airway protection and bolus control despite impaired cerebellar timing. National Ataxia Foundation

6) Occupational therapy (OT)
OT focuses on hand coordination (buttoning, writing), energy conservation, and home/work adaptations (grab bars, non-slip mats, kitchen setup). Adaptive tools (weighted utensils, pen grips) reduce tremor impact and save time. Purpose: keep daily tasks doable and safe. Mechanism: task modification + assistive devices reduce motor demands and leverage intact sensory feedback. PMC

7) Fall-prevention program & home safety audit
A therapist evaluates lighting, clutter, thresholds, and bathroom safety, then recommends rails, shower seats, and footwear. Combined with balance training, this reduces falls and injuries. Purpose: prevent fractures, hospitalizations, and fear-of-falling. Mechanism: environmental risk reduction + improved balance lowers slip/trip risk. PMC

8) Walking aids (cane, trekking poles, rollator)
Selecting the right device (and proper height) stabilizes gait and increases endurance. Instruction in turning, curb negotiation, and dual-task walking is important. Purpose: mobility with fewer stumbles. Mechanism: increases base of support and external stability to compensate for limb/trunk ataxia. PMC

9) Ankle-foot orthoses (AFO) / sensory insoles
For severe ankle sway or foot-drop, carbon or hinged AFOs and proprioceptive insoles improve foot placement and stance control. Purpose: steadier steps and reduced effort. Mechanism: mechanical alignment + enhanced sensory input improves step timing. PMC

10) Task-specific handwriting & fine-motor practice
Short daily practice of large-to-small lettering, guiding lines, and weighted pens improves legibility. Purpose: better written communication. Mechanism: repetitive visuomotor calibration supports compensatory cortical planning. PMC

11) Visual strategies for nystagmus
Optometric assessment and simple aids—like prism lenses and target-fixation drills—may reduce reading blur; pairing with vestibular therapy often helps. Purpose: reduce oscillopsia and eye strain. Mechanism: optical realignment + oculomotor training enhances foveation time. PMC

12) Aerobic & strength conditioning
Moderate aerobic activity (walking, cycling) 150 minutes/week plus 2–3 strength sessions maintains endurance, bone health, and fall resilience. Gradual build-ups are safe with monitoring. Purpose: stamina, mood, and bone/muscle protection. Mechanism: cardio-metabolic benefits and neuromuscular reserve. National Ataxia Foundation

13) Cueing & rhythm-based training
Metronome beats or rhythmic music can smooth stepping and reduce hesitations. Purpose: steadier cadence and fewer freezes. Mechanism: external timing cues bypass noisy internal timing. PMC

14) Exergaming & home video programs
Interactive balance games and structured online exercise videos keep people engaged between therapy sessions and can improve confidence. Purpose: adherence and motivation. Mechanism: gamified repetitions reinforce motor learning. National Ataxia Foundation

15) Cognitive-behavioral strategies & mood support
CBT, peer support, and caregiver training reduce anxiety, fear-of-falling, and isolation—common in slowly progressive neurological disease. Purpose: protect mental health and participation. Mechanism: coping skills reshape behavior and reduce avoidance. PMC

16) Nutrition counseling
SLP + dietitian help optimize textures, hydration, and calorie density to maintain weight and medication timing (e.g., avoiding fatigue from under-nutrition). Purpose: adequate energy and safe eating. Mechanism: tailored textures and meal timing reduce aspiration and fatigue. National Ataxia Foundation

17) Sleep hygiene & daytime energy pacing
Regular schedules, light exposure, and paced activity blocks fight fatigue and improve therapy tolerance. Purpose: more usable daytime energy. Mechanism: circadian stabilization + energy conservation. PMC

18) Transcranial direct current stimulation (tDCS)
Small studies and meta-analyses show that cerebellar tDCS can modestly improve ataxia scores for weeks to months. It is investigational and should be done in research-experienced clinics. Purpose: adjunct to therapy for motor symptoms. Mechanism: non-invasive modulation enhances cerebello-cortical excitability and motor learning. PMC+1

19) Transcranial alternating current stimulation (tACS)
Early research suggests cerebellar-targeted tACS may improve motor functions; clinical use remains investigational pending larger trials. Purpose: potential adjunct to rehab. Mechanism: frequency-specific entrainment of cerebellar networks. Cell

20) Advance care planning & genetic counseling
Discuss fall-safety, work adaptations, future mobility aids, and nutrition strategies early. Offer genetic counseling for family planning because SCAR10 is recessive and siblings may be carriers. Purpose: informed choices, reduced uncertainty. Mechanism: risk education and proactive planning mitigate downstream complications. NCBI

---

Drug Treatments

Important: None of these is approved to cure SCAR10. They are used to treat symptoms such as spasticity, tremor, dystonia, seizures, neuropathic pain, mood, fatigue, dizziness, nystagmus, or orthostatic hypotension. Doses are typical adult ranges—your clinician will individualize and monitor side effects.

1) Baclofen (oral) – spasticity/stiffness
Class: GABA-B agonist. Dose/Time: Often 5 mg 3×/day titrated to 10–20 mg 3–4×/day; taper slowly. Purpose: reduce muscle tone and spasms that worsen gait. Mechanism: enhances spinal inhibition. Side effects: sleepiness, weakness, dizziness; abrupt stop can cause withdrawal. FDA labeling supports safety/risks for spasticity (Lioresal and generics). FDA Access Data

2) Tizanidine – spasticity
Class: α2-adrenergic agonist. Dose: Start 2 mg up to every 6–8 h; titrate (max often 36 mg/day). Purpose: relaxes muscles with less weakness than some alternatives. Mechanism: presynaptic inhibition in spinal cord. Side effects: sedation, dry mouth, low blood pressure, liver enzyme elevations (monitor). FDA Access Data

3) Intramuscular onabotulinumtoxinA – focal dystonia/spasticity
Class: neuromuscular blocker. Dose: localized injections every ~12 weeks tailored to pattern (e.g., calf/clawed toes). Purpose: targets troublesome muscles without systemic sedation. Mechanism: blocks acetylcholine release at nerve terminals. Side effects: weakness in injected muscles, flu-like symptoms. FDA Access Data

4) Clonazepam – myoclonus/tremor/anxiety
Class: benzodiazepine. Dose: 0.25–0.5 mg at night, titrate to effect (lowest effective dose). Purpose: dampens jerks and anxiety related to imbalance. Mechanism: GABA-A potentiation. Side effects: sedation, falls, dependence risk. FDA Access Data

5) Propranolol – action tremor
Class: non-selective β-blocker. Dose: 10–20 mg 2–3×/day or LA 60–120 mg/day as tolerated. Purpose: improves action tremor that amplifies clumsiness. Mechanism: peripheral β-blockade reduces tremulous drive. Side effects: fatigue, low heart rate, bronchospasm in asthma. FDA Access Data

6) Levetiracetam – seizures/myoclonus
Class: antiepileptic (SV2A binder). Dose: often 500 mg 2×/day; adjust for kidneys. Purpose: control seizures reported in some SCAR10 cases. Mechanism: modulates synaptic vesicle release. Side effects: mood changes, irritability, sleepiness. FDA Access Data

7) Valproate (valproic acid/sodium) – generalized seizures
Class: broad-spectrum antiepileptic. Dose: individualized; monitor liver function and drug levels. Purpose: alternative for seizure control. Mechanism: increases GABA and reduces excitability. Side effects: weight gain, tremor, hepatotoxicity; major teratogenicity—avoid in pregnancy/child-bearing without strict indication. FDA Access Data

8) Topiramate – seizures/migraine; sometimes tremor
Class: antiepileptic (multiple targets). Dose: slow titration (e.g., 25 mg nightly increasing weekly). Purpose: seizure control; may help migraine that worsens balance. Mechanism: sodium channel block, GABA enhancement, glutamate antagonism. Side effects: cognitive slowing, paresthesia, weight loss, kidney stones. FDA Access Data

9) Acetazolamide – episodic nystagmus/ataxia components
Class: carbonic anhydrase inhibitor. Dose: 125–250 mg 1–3×/day (specialist guided). Purpose: occasionally used for downbeat nystagmus or episodic features. Mechanism: pH shifts modulate cerebellar firing. Side effects: tingling, fatigue, kidney stones; avoid in sulfonamide allergy. FDA Access Data

10) Amantadine (immediate- or extended-release)
Class: NMDA antagonist/ dopaminergic effects. Dose: IR 100 mg 1–2×/day; ER dosing per label. Purpose: fatigue, gait initiation, or dyskinesia-like movements. Mechanism: modulates glutamate and dopamine. Side effects: hallucinations, ankle edema, livedo reticularis, insomnia. FDA Access Data

11) Dalfampridine (fampridine) – gait speed adjunct
Class: potassium-channel blocker. Dose: 10 mg twice daily (renal restrictions; seizure risk with higher doses). Purpose: in selected patients with slow gait, may improve walking speed (approved in MS; off-label in ataxia under specialist care). Mechanism: enhances conduction in demyelinated or dysfunctional axons. Side effects: insomnia, dizziness; avoid if history of seizures or low kidney function. FDA Access Data

12) Riluzole – neuroexcitability modulator
Class: glutamate modulator. Dose: 50 mg twice daily with liver monitoring. Purpose: investigated in hereditary ataxias; sometimes tried off-label for gait/ataxia. Mechanism: reduces glutamatergic excitotoxicity. Side effects: liver enzyme elevation, nausea, dizziness. FDA Access Data

13) Gabapentin – neuropathic pain/ataxia discomfort
Class: α2δ calcium-channel ligand. Dose: 100–300 mg at night, titrate to 300–600 mg 3×/day as tolerated. Purpose: treat nerve pain or paresthesias that worsen sleep and function. Mechanism: reduces abnormal excitatory neurotransmission. Side effects: dizziness, sedation, ataxia (start low). FDA Access Data

14) Pregabalin – neuropathic pain/anxiety
Class: α2δ ligand. Dose: 50–75 mg 2–3×/day; renal adjustment. Purpose: nerve pain control and calming effect. Mechanism: dampens calcium-dependent neurotransmitter release. Side effects: dizziness, edema, weight gain. FDA Access Data

15) Duloxetine – neuropathic pain & mood
Class: SNRI. Dose: 30–60 mg/day. Purpose: treats neuropathic pain and comorbid depression/anxiety common in chronic neurologic disease. Mechanism: boosts serotonin/norepinephrine in pain pathways. Side effects: nausea, dry mouth, BP changes. FDA Access Data

16) Amitriptyline – neuropathic pain & sleep
Class: tricyclic antidepressant. Dose: 10–25 mg at night; titrate carefully. Purpose: pain and insomnia relief. Mechanism: inhibits reuptake of serotonin/norepinephrine and modulates descending pain control. Side effects: dry mouth, constipation, daytime drowsiness. FDA Access Data

17) Modafinil – excessive daytime sleepiness/fatigue
Class: wake-promoting agent. Dose: 100–200 mg in the morning. Purpose: improves daytime alertness to engage in therapy and activities. Mechanism: enhances wake circuits (exact pathways multifactorial). Side effects: headache, insomnia, anxiety; rare rash. FDA Access Data

18) Sertraline – depression/anxiety
Class: SSRI. Dose: 25–50 mg/day, titrate to 50–200 mg/day. Purpose: mood stabilization improves participation in rehab and quality of life. Mechanism: increases synaptic serotonin. Side effects: GI upset, sexual side effects; taper slowly to avoid discontinuation symptoms. FDA Access Data

19) Quetiapine – sleep/anxiety/behavioral agitation (low dose)
Class: atypical antipsychotic. Dose: often 12.5–25 mg at night; use lowest effective dose. Purpose: adjunct for severe insomnia/anxiety or behavioral dysregulation under specialist supervision. Mechanism: multi-receptor modulation (5-HT2A/D2). Side effects: sedation, metabolic effects; boxed warnings in elderly with dementia. FDA Access Data

20) Midodrine – orthostatic hypotension
Class: α1-agonist. Dose: 2.5–10 mg during daytime; avoid near bedtime. Purpose: raises standing blood pressure to reduce dizziness/falls if autonomic symptoms coexist. Mechanism: constricts veins/arteries to maintain pressure. Side effects: scalp tingling, supine hypertension (monitor). FDA Access Data

---

Dietary Molecular Supplements

1) Coenzyme Q10 (CoQ10; 100–300 mg/day with food)
CoQ10 supports mitochondrial energy production (electron transport) and acts as an antioxidant. Some hereditary ataxias show CoQ10 deficiency, and isolated reports suggest symptomatic benefit in select patients; evidence is mixed. Consider a trial if fatigue or biopsy-proven deficiency is present. Mechanism: improves ATP generation and scavenges reactive oxygen species in neurons. Note: can interact with anticoagulants; quality varies by brand. NCBI+1

2) Vitamin E (natural d-alpha-tocopherol; 200–400 IU/day unless told otherwise)
Vitamin E protects cell membranes from oxidative damage. It is essential for neurologic function, and severe deficiency causes ataxia in other conditions. High doses carry bleeding risk; stay within clinician-advised amounts. Mechanism: lipid-phase antioxidant stabilizing neuronal membranes. Office of Dietary Supplements

3) Thiamin (Vitamin B1; 50–100 mg/day short term for deficiency risk)
B1 enables carbohydrate metabolism and nerve energy production. Certain patients at nutritional risk (poor intake, malabsorption) may benefit from repletion to optimize nerve function. Mechanism: cofactor for pyruvate dehydrogenase/α-ketoglutarate dehydrogenase in mitochondrial ATP production. Office of Dietary Supplements

4) Riboflavin (Vitamin B2; 25–100 mg/day if deficient)
Riboflavin supports flavoproteins (FAD/FMN) in mitochondrial electron transport. Adequate levels may support energy pathways used by cerebellar neurons. Mechanism: cofactor in redox reactions and antioxidant recycling. Office of Dietary Supplements

5) Alpha-lipoic acid (ALA; 300–600 mg/day)
ALA is an antioxidant cofactor that recycles other antioxidants and may support mitochondrial enzymes. Limited neurologic data; avoid in pregnancy without advice and monitor glucose if diabetic. Mechanism: redox cycling and mitochondrial coenzyme activity. Office of Dietary Supplements

6) Omega-3 fatty acids (EPA/DHA; 1–2 g/day total, with meals)
Omega-3s support neuronal membranes and have anti-inflammatory effects. They may aid general brain health and cardiovascular protection in chronic illness. Mechanism: membrane fluidity modulation and pro-resolving mediators. Office of Dietary Supplements

7) Vitamin D3 (cholecalciferol; dose per blood level, often 800–2000 IU/day)
Supports bone health (reduces fracture risk from falls) and immune balance. Mechanism: nuclear receptor signaling influencing calcium/bone metabolism and immune pathways. Office of Dietary Supplements

8) Magnesium (200–400 mg elemental/day as citrate or glycinate)
Magnesium participates in neuromuscular excitability and energy metabolism; correction of low levels may reduce cramps and improve sleep quality. Mechanism: NMDA receptor modulation and ATP cofactor. Office of Dietary Supplements

9) N-acetylcysteine (NAC; 600–1200 mg/day)
Precursor to glutathione, a key brain antioxidant; studied in several neurologic conditions for oxidative stress. Mechanism: replenishes glutathione and reduces oxidative injury. Office of Dietary Supplements

10) Creatine monohydrate (3–5 g/day)
Creatine buffers cellular energy (phosphocreatine system). While evidence in ataxia is limited, it may help muscle fatigue and exercise tolerance when paired with therapy. Mechanism: enhances rapid ATP regeneration in muscle/neurons. Office of Dietary Supplements

---

Immunity-booster / Regenerative / Stem-cell Drugs

Honest note: There are no approved immune or stem-cell drugs for SCAR10. The options below are research-stage or off-label; discuss risks in a specialist center.

1) Troriluzole (BHV-4157; investigational glutamate modulator)
Extended-release prodrug of riluzole studied in SCA. Recent phase-3/topline and long-term analyses suggest slowed progression and reduced falls in subgroups; FDA review is being discussed. Not yet approved for SCA. Mechanism: normalizes glutamatergic tone to reduce excitotoxic stress in cerebellar circuits. Dose: per trial protocols. Function: potential disease-slowing adjunct. STAT+3Reuters+3ir.biohaven.com+3

2) Mesenchymal stem cells (MSCs; investigational)
Small studies (intravenous/intrathecal) in SCA suggest safety and possible functional signals; high-quality randomized data are limited, and benefits remain unproven. Mechanism: paracrine neurotrophic and anti-inflammatory signaling; potential synaptic support. Function: experimental neurorestorative approach in trials only. PMC+1

3) N-acetyl-L-leucine (or DL-leucine; investigational)
Amino-acid derivative tested for symptomatic ataxia. A large crossover RCT did not show overall benefit across mixed ataxias; some ongoing studies explore specific genotypes. Mechanism: proposed cerebellar membrane/ion effects. Function: investigational; not standard care. JAMA Network+1

4) Varenicline (off-label; nicotinic partial agonist)
In SCA3, a randomized study found improvements in axial/gait SARA subscores; evidence is genotype-specific and modest. Mechanism: α4β2 nicotinic receptor modulation affecting cerebellar networks. Function: selected off-label trial under specialist monitoring. Dose: per label for smoking cessation when used. PubMed+1

5) Cerebellar neuromodulation (tDCS/tACS; device-based)
Though not a “drug,” non-invasive stimulation is being studied as a regenerative adjunct that may enhance plasticity and motor learning when paired with therapy. Function: symptom easing and training gains. Mechanism: polarity/frequency-dependent modulation of cerebello-cortical circuits. PMC+1

6) CoQ10 (adjunct when deficiency is found)
In some recessive ataxias, low muscle CoQ10 was reported and improved with supplementation; SCAR10 data are limited. Function: supportive mitochondrial cofactor when deficient. Mechanism: electron transport antioxidant. Dose: individualized. NCBI

---

Procedures / Surgeries

1) PEG (feeding tube) placement
When severe swallowing impairment causes weight loss or aspiration risk, a percutaneous endoscopic gastrostomy provides safe nutrition/hydration and medication delivery. Why: prevent pneumonia, maintain weight, and support energy for therapy. National Ataxia Foundation

2) Intrathecal baclofen pump
For severe, generalized spasticity not controlled by pills, a programmable pump delivers baclofen to spinal fluid, improving tone with fewer systemic effects. Why: reduce stiffness, pain, and falls; enable easier care/mobility. FDA Access Data

3) Deep brain stimulation (DBS) for refractory tremor
In highly selected cases with disabling intention tremor, DBS targeting thalamic circuits may reduce tremor amplitude; effect on pure ataxia is limited. Why: regain function in tasks like feeding/writing when other treatments fail. PMC

4) Orthopedic procedures (e.g., tendon lengthening, foot deformity correction, spinal stabilization)
If long-standing imbalance leads to painful deformities or scoliosis, surgery can realign joints and improve bracing tolerance. Why: pain relief, better shoe/bracing fit, safer stance. PMC

5) Vision procedures / prism fitting (by neuro-ophthalmology/optometry)
Prism lenses or strabismus procedures are rarely used to help severe gaze issues; more commonly, prisms are fitted without surgery. Why: reduce disabling oscillopsia and improve reading. PMC

---

Preventions

1. Genetic counseling for family planning and carrier testing. NCBI

2. Home fall-proofing (lighting, rails, remove rugs/clutter). PMC

3. Strength/balance training 3–5×/week to maintain mobility. Frontiers

4. Vaccinations (influenza/pneumococcal) to prevent infections that worsen function. PMC

5. Medication review—avoid sedatives/alcohol excess that increase falls. PMC

6. Bone health (vitamin D, weight-bearing, fall prevention) to prevent fracture. Office of Dietary Supplements

7. Nutrition & swallow monitoring to prevent aspiration and weight loss. National Ataxia Foundation

8. Vision care (prisms/oculomotor exercises) to reduce visual blur–related falls. PMC

9. Orthostatic hypotension management (fluids, compression, meds if needed). FDA Access Data

10. Regular therapy follow-ups to refresh home programs and adapt devices. PMC

---

When to See Doctors (red flags)

Contact your neurologist or urgent care if you notice sudden worsening of balance or speech, new seizures, repeated choking, unexplained weight loss, frequent falls, fainting on standing, or major mood changes (depression, suicidal thoughts). New, fast changes can reflect infections, medication side effects, dehydration, B-vitamin deficiencies, or other treatable problems layered onto SCAR10. Early evaluation helps adjust medications, update therapy plans, and prevent complications like pneumonia or fractures. NCBI

---

What to Eat” & What to Avoid”

Eat more of:

• Soft-moist proteins & fiber-rich foods (easier to chew/swallow; keep energy up). National Ataxia Foundation

• Hydrating soups/smoothies if swallowing thin liquids is safe as advised by SLP. National Ataxia Foundation

• Healthy fats (olive oil, omega-3 fish) to maintain calories and brain-healthy lipids. Office of Dietary Supplements

• Colorful fruits/vegetables for antioxidants supporting general brain health. Office of Dietary Supplements

• Adequate calcium/vitamin D sources for bone protection if falls occur. Office of Dietary Supplements

Limit/avoid:

• Alcohol excess and sedatives that worsen balance and speech. PMC

• Very dry/crumbly foods (toast, dry rice) if choking—unless SLP clears. National Ataxia Foundation

• Large, hurried meals—use small frequent meals to reduce fatigue. National Ataxia Foundation

• Dehydration—sip fluids through the day (per SLP safety guidance). National Ataxia Foundation

• Ultra-high doses of supplements without labs/medical review (e.g., high vitamin E can increase bleeding risk). Office of Dietary Supplements

---

Frequently Asked Questions (FAQs)

1) Is SCAR10 the same as “SCA10”?
No. SCA10 is an autosomal-dominant repeat-expansion disorder; SCAR10 is autosomal-recessive due to ANO10 variants. They share “ataxia” but have different genetics and inheritance. NCBI+1

2) How is SCAR10 diagnosed?
By clinical exam, brain MRI showing cerebellar atrophy, and genetic testing confirming biallelic ANO10 variants. Other causes of ataxia are excluded first. NCBI

3) Can SCAR10 be cured?
No approved cure exists today. Management focuses on rehabilitation, safety, and symptom control; multiple clinical trials are ongoing. PMC

4) Will exercise really help if the cerebellum is degenerating?
Yes—structured physiotherapy consistently shows meaningful improvements in function and confidence, especially when maintained long-term. Frontiers

5) Is tDCS a standard treatment?
Not yet. Trials suggest modest benefits in ataxia severity; it’s considered investigational and should be delivered in experienced centers. PMC

6) Do any medicines slow SCAR10?
No medicine is FDA-approved to slow SCAR10. Troriluzole has encouraging SCA data under FDA review; results remain investigational for clinical use. Reuters

7) What about stem-cell therapy abroad?
Small early studies suggest safety but no definitive efficacy; risks and costs are significant. Enroll only in regulated clinical trials. PMC

8) Could vitamins fix the ataxia?
Vitamins support health but do not cure SCAR10. Treat proven deficiencies (e.g., vitamin D) and avoid mega-doses without a clinician’s guidance. Office of Dietary Supplements

9) Are seizures common?
Seizures are reported in some patients but not all; if present, standard anti-seizure medicines are used. NCBI

10) Can vision problems be helped?
Yes—vestibular therapy, oculomotor exercises, and occasionally prism lenses can reduce oscillopsia and improve reading. PMC

11) Is work still possible?
Many people continue working with accommodations (flexible hours, seating, device use). OT can help with adaptations. PMC

12) How do we plan for the future?
Regular rehab blocks, home safety updates, mobility aids, and nutrition reviews help maintain independence; consider genetic counseling for family planning. NCBI

13) What increases fall risk most?
Poor lighting, loose rugs, hurried multitasking, sedating medicines, and dehydration commonly trigger falls. PMC

14) How often should I follow up?
Typically every 6–12 months with neurology and more often with PT/OT/SLP during changes; sooner if abrupt worsening or new symptoms occur. PMC

15) Where can I read more about ANO10 and SCAR10?
See OMIM/MedGen summaries and recent reviews on ANO10 biology and SCAR10 clinical features. NCBI+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 13, 2025.

PDF Documents For This Disease Condition References